Ensembles of uncertain mathematical models can identify network response to therapeutic interventions.
暂无分享,去创建一个
Deyan Luan | Jeffrey D Varner | Fania Szlam | Kenichi A Tanaka | Philip S Barie | P. Barie | J. Varner | D. Luan | Kenichi A. Tanaka | F. Szlam
[1] K. Danø,et al. Plasminogen activation by receptor-bound urokinase. A kinetic study with both cell-associated and isolated receptor. , 1991, The Journal of biological chemistry.
[2] I. Ghareeb,et al. Differential detection of GMSK signals with postdetection MRC over correlated and unbalanced Nakagami-m fading channels , 2005 .
[3] R J Leipold,et al. Mathematical Model of Serine Protease Inhibition in the Tissue Factor Pathway to Thrombin (*) , 1995, The Journal of Biological Chemistry.
[4] K. Danø,et al. Plasminogen Activation by Receptor-Bound Urokinase , 1991, Seminars in thrombosis and hemostasis.
[5] Fania Szlam,et al. In-vitro evaluation of anti-factor IXa aptamer on thrombin generation, clotting time, and viscoelastometry , 2009, Thrombosis and Haemostasis.
[6] F J Doyle,et al. Model identification of signal transduction networks from data using a state regulator problem. , 2005, Systems biology.
[7] K. Mann,et al. "Normal" thrombin generation. , 1999, Blood.
[8] Kwang-Hyun Cho,et al. Experimental Design in Systems Biology, Based on Parameter Sensitivity Analysis Using a Monte Carlo Method: A Case Study for the TNFα-Mediated NF-κ B Signal Transduction Pathway , 2003, Simul..
[9] B. Wiman,et al. On the kinetics of the reaction between human antiplasmin and plasmin. , 1978, European journal of biochemistry.
[10] K. H. Lee,et al. The statistical mechanics of complex signaling networks: nerve growth factor signaling , 2004, Physical biology.
[11] C. Longstaff,et al. The regulation by fibrinogen and fibrin of tissue plasminogen activator kinetics and inhibition by plasminogen activator inhibitor 1 , 2007, Journal of thrombosis and haemostasis : JTH.
[12] N. Booth,et al. Thrombus lysis by uPA, scuPA and tPA is regulated by plasma TAFI , 2003, Journal of thrombosis and haemostasis : JTH.
[13] Giuseppe Lippi,et al. Pharmacogenetics of vitamin K antagonists: useful or hype? , 2009, Clinical chemistry and laboratory medicine.
[14] Dougald M Monroe,et al. The use of recombinant factor VIIa in the treatment of bleeding disorders. , 2004, Blood.
[15] P. Majerus,et al. The interaction of human coagulation factor Va with platelets. , 1982, The Journal of biological chemistry.
[16] F. Doyle,et al. A benchmark for methods in reverse engineering and model discrimination: problem formulation and solutions. , 2004, Genome research.
[17] S. Diamond,et al. Systems biology to predict blood function , 2009, Journal of thrombosis and haemostasis : JTH.
[18] A. Fogelson,et al. Surface-mediated control of blood coagulation: the role of binding site densities and platelet deposition. , 2001, Biophysical journal.
[19] Julia Mitchell,et al. Haemophilia and inhibitors. 1: Diagnosis and treatment. , 2008, Nursing times.
[20] P. Perrotta,et al. Platelet activation in a circulating flow loop: combined effects of shear stress and exposure time , 2003, Platelets.
[21] J. Arnold,et al. An ensemble method for identifying regulatory circuits with special reference to the qa gene cluster of Neurospora crassa , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[22] Dougald M Monroe,et al. Manipulation of prothrombin concentration improves response to high‐dose factor VIIa in a cell‐based model of haemophilia , 2006, British journal of haematology.
[23] Y. Nakatomi,et al. A novel therapeutic approach combining human plasma‐derived Factors VIIa and X for haemophiliacs with inhibitors: evidence of a higher thrombin generation rate in vitro and more sustained haemostatic activity in vivo than obtained with Factor VIIa alone , 2003, Vox sanguinis.
[24] Eduardo Sontag,et al. Untangling the wires: A strategy to trace functional interactions in signaling and gene networks , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[25] D. Atsma,et al. Development of a new test for the global fibrinolytic capacity in whole blood , 2007, Journal of thrombosis and haemostasis : JTH.
[26] K Kolev,et al. Regulation of fibrinolytic activity of neutrophil leukocyte elastase, plasmin, and miniplasmin by plasma protease inhibitors. , 1994, The Journal of biological chemistry.
[27] Y Komiyama,et al. Proteolytic activation of human factors IX and X by recombinant human factor VIIa: effects of calcium, phospholipids, and tissue factor. , 1990, Biochemistry.
[28] James H Morrissey,et al. Polyphosphate modulates blood coagulation and fibrinolysis. , 2006, Proceedings of the National Academy of Sciences of the United States of America.
[29] G Pohl,et al. Plasminogen activator inhibitor type-1 interacts exclusively with the proteinase domain of tissue plasminogen activator. , 1994, Biochimica et biophysica acta.
[30] Christopher R. Myers,et al. Universally Sloppy Parameter Sensitivities in Systems Biology Models , 2007, PLoS Comput. Biol..
[31] A. Shapiro,et al. Single-dose recombinant activated factor VII for the treatment of joint bleeds in hemophilia patients with inhibitors. , 2008, Clinical advances in hematology & oncology : H&O.
[32] David R. Corey,et al. Substrate Specificity of Tissue Type Plasminogen Activator , 1995, The Journal of Biological Chemistry.
[33] M. Schenone,et al. The blood coagulation cascade , 2004, Current opinion in hematology.
[34] J. Oliver,et al. Platelet activity of high‐dose factor VIIa is independent of tissue factor , 1997, British journal of haematology.
[35] Kazuo Fujikawa,et al. Historical perspective of factor XI. , 2005, Thrombosis research.
[36] Martin Zenker,et al. Influence of soluble fibrin on reaction kinetics of plasmin type 1 and type 2 with α2-antiplasmin , 2003, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.
[37] S W Hall,et al. Inhibition of cell surface receptor-bound plasmin by alpha 2-antiplasmin and alpha 2-macroglobulin. , 1991, The Journal of biological chemistry.
[38] J. Badimón,et al. Blood-borne tissue factor: another view of thrombosis. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[39] M. Boffa,et al. Plasma and Recombinant Thrombin-activable Fibrinolysis Inhibitor (TAFI) and Activated TAFI Compared with Respect to Glycosylation, Thrombin/Thrombomodulin-dependent Activation, Thermal Stability, and Enzymatic Properties* , 1998, The Journal of Biological Chemistry.
[40] H. Kitano. A robustness-based approach to systems-oriented drug design , 2007, Nature Reviews Drug Discovery.
[41] S. Thorsen,et al. Kinetics of inhibition of tissue-type and urokinase-type plasminogen activator by plasminogen-activator inhibitor type 1 and type 2. , 1988, European journal of biochemistry.
[42] J. Bailey. Complex biology with no parameters , 2001, Nature Biotechnology.
[43] Kumbakonam R. Rajagopal,et al. A Model Incorporating Some of the Mechanical and Biochemical Factors Underlying Clot Formation and Dissolution in Flowing Blood , 2003 .
[44] K. Mann,et al. A model for the tissue factor pathway to thrombin. II. A mathematical simulation. , 1994, The Journal of biological chemistry.
[45] Shapiro,et al. A randomized, double‐blind comparison of two dosage levels of recombinant factor VIIa in the treatment of joint, muscle and mucocutaneous haemorrhages in persons with haemophilia A and B, with and without inhibitors , 1998 .
[46] M. Nesheim,et al. A Study of the Protection of Plasmin from Antiplasmin Inhibition within an Intact Fibrin Clot during the Course of Clot Lysis* , 2004, Journal of Biological Chemistry.
[47] K. Mann,et al. Mechanism of factor VIIa-dependent coagulation in hemophilia blood. , 2002, Blood.
[48] Christopher R. Myers,et al. Optimal experimental design in an EGFR signaling and down-regulation model , 2006, q-bio/0610024.
[49] D. Siegel,et al. Acute myocardial infarction during treatment with an activated prothrombin complex concentrate in a patient with factor VIII deficiency and a factor VIII inhibitor. , 1988, The American journal of medicine.
[50] Joseph M. Scandura,et al. Structural and Functional Characterization of Platelet Receptor-mediated Factor VIII Binding* , 2000, The Journal of Biological Chemistry.
[51] S. Coughlin,et al. Thrombin signalling and protease-activated receptors , 2000, Nature.
[52] L. Sottrup-jensen,et al. Stopped-flow fluorescence kinetics of bovine alpha 2-antiplasmin inhibition of bovine midiplasmin. , 1995, The Biochemical journal.
[53] F B Taylor,et al. Alpha-2-macroglobulin functions as an inhibitor of fibrinolytic, clotting, and neutrophilic proteinases in sepsis: studies using a baboon model , 1993, Infection and immunity.
[54] Kenichi A Tanaka,et al. Blood Coagulation: Hemostasis and Thrombin Regulation , 2009, Anesthesia and analgesia.
[55] M. Nesheim,et al. Activated Thrombin-activatable Fibrinolysis Inhibitor Reduces the Ability of High Molecular Weight Fibrin Degradation Products to Protect Plasmin from Antiplasmin* , 2004, Journal of Biological Chemistry.
[56] K. Mann,et al. Thrombin functions during tissue factor-induced blood coagulation. , 2002, Blood.
[57] Celia Arnaud. DRIVING A SPIKE INTO VIRUSES , 2006 .
[58] Zhiliang Xu,et al. A multiscale model of thrombus development , 2008, Journal of The Royal Society Interface.
[59] David Garcia,et al. Novel anticoagulants and the future of anticoagulation. , 2009, Thrombosis research.
[60] K Fujikawa,et al. Activation of human blood coagulation factor XI independent of factor XII. Factor XI is activated by thrombin and factor XIa in the presence of negatively charged surfaces. , 1991, The Journal of biological chemistry.
[61] G. Hansson. Inflammation, atherosclerosis, and coronary artery disease. , 2005, The New England journal of medicine.
[62] G. Müller‐Berghaus,et al. Discrimination between fibrin and fibrinogen by a monoclonal antibody against a synthetic peptide. , 1985, Proceedings of the National Academy of Sciences of the United States of America.
[63] D. Loskutoff,et al. Historical analysis of PAI-1 from its discovery to its potential role in cell motility and disease , 2005, Thrombosis and Haemostasis.
[64] Stefan Roth,et al. Covariance Matrix Adaptation for Multi-objective Optimization , 2007, Evolutionary Computation.
[65] Celia Arnaud. Systems biology's clinical future , 2006 .
[66] Anne Dell,et al. Differences between neonates and adults in carbohydrate sequences and reaction kinetics of plasmin and alpha(2)-antiplasmin. , 2002, Thrombosis research.
[67] G. Young,et al. Sequential therapy with activated prothrombin complex concentrates and recombinant FVIIa in patients with severe haemophilia and inhibitors: update of our previous experience , 2007, Haemophilia : the official journal of the World Federation of Hemophilia.
[68] C. Kessler,et al. Newer concepts of blood coagulation , 1998, Haemophilia : the official journal of the World Federation of Hemophilia.
[69] Eduardo D. Sontag,et al. Inferring dynamic architecture of cellular networks using time series of gene expression, protein and metabolite data , 2004, Bioinform..
[70] Kenneth G. Mann,et al. Inhibitory Mechanism of the Protein C Pathway on Tissue Factor-induced Thrombin Generation , 1997, The Journal of Biological Chemistry.
[71] K. C. Jones,et al. A Model for the Stoichiometric Regulation of Blood Coagulation* , 2002, The Journal of Biological Chemistry.
[72] P. Walsh,et al. Platelet receptor occupancy with factor IXa promotes factor X activation. , 1989, The Journal of biological chemistry.
[73] F. Allgöwer,et al. Robustness properties of apoptosis models with respect to parameter variations and intrinsic noise. , 2005, Systems biology.
[74] H. Roberts,et al. Activated factor VII activates factors IX and X on the surface of activated platelets: thoughts on the mechanism of action of high-dose activated factor VII. , 1998, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.
[75] K. Rajagopal,et al. A Model for the Formation and Lysis of Blood Clots , 2006, Pathophysiology of Haemostasis and Thrombosis.
[76] Kenneth G. Mann,et al. Surface-dependent reactions of the vitamin K-dependent enzyme complexes , 1990 .
[77] J. Deinum,et al. The Importance of Enzyme Inhibition Kinetics for the Effect of Thrombin Inhibitors in a Rat Model of Arterial Thrombosis , 1997, Thrombosis and Haemostasis.
[78] Michael R Pinsky,et al. Current Evidence Based Guidelines for Factor VIIa Use in Trauma: The Good, the Bad, and the Ugly , 2008, The American surgeon.
[79] M. Rånby,et al. Studies on the kinetics of plasminogen activation by tissue plasminogen activator. , 1982, Biochimica et biophysica acta.
[80] J. Stelling,et al. Robustness properties of circadian clock architectures. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[81] Fania Szlam,et al. Effects of antithrombin and heparin cofactor II levels on anticoagulation with Intimatan , 2005, Thrombosis and Haemostasis.
[82] A D Shapiro,et al. Recombinant Factor VIIa in the Treatment of Bleeding in Hemophilic Children with Inhibitors , 2000, Seminars in thrombosis and hemostasis.
[83] K. S. Brown,et al. Optimal experimental design in an epidermal growth factor receptor signalling and down-regulation model. , 2007, IET systems biology.
[84] P. Carmeliet,et al. Clotting Factors Build Blood Vessels , 2001, Science.
[85] S. Olson,et al. Role of the antithrombin-binding pentasaccharide in heparin acceleration of antithrombin-proteinase reactions. Resolution of the antithrombin conformational change contribution to heparin rate enhancement. , 1992, The Journal of biological chemistry.
[86] K. Mann,et al. Complex-dependent inhibition of factor VIIa by antithrombin III and heparin. , 1993, The Journal of biological chemistry.
[87] Deyan Luan,et al. Computationally Derived Points of Fragility of a Human Cascade Are Consistent with Current Therapeutic Strategies , 2007, PLoS Comput. Biol..
[88] S. Coughlin,et al. How the protease thrombin talks to cells. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[89] C. Danforth,et al. The impact of uncertainty in a blood coagulation model. , 2009, Mathematical medicine and biology : a journal of the IMA.
[90] H. Hemker,et al. Factor XI–Dependent Reciprocal Thrombin Generation Consolidates Blood Coagulation when Tissue Factor Is Not Available , 2004, Arteriosclerosis, thrombosis, and vascular biology.
[91] E G Tuddenham,et al. The hemophilias--from royal genes to gene therapy. , 2001, The New England journal of medicine.
[92] J. Maraganore,et al. Kinetic mechanism for the interaction of Hirulog with thrombin. , 1994, Biochemistry.
[93] J. Griffin,et al. Purification and characterization of plasma protein C inhibitor. , 1989, Thrombosis research.
[94] U. Hedner,et al. Factor VIIa and its potential therapeutic use in bleeding-associated pathologies , 2008, Thrombosis and Haemostasis.
[95] Chiara Dall’Asta,et al. Oral factor Xa inhibitors for thromboprophylaxis in major orthopedic surgery: a review , 2009, Internal and emergency medicine.
[96] A D Shapiro,et al. Prospective, Randomised Trial of Two Doses of rFVIIa (NovoSeven) in Haemophilia Patients with Inhibitors Undergoing Surgery , 1998, Thrombosis and Haemostasis.
[97] L. You,et al. Evolutionary design on a budget: robustness and optimality of bacteriophage T7. , 2006, Systems biology.
[98] Peter J. Fleming,et al. An Overview of Evolutionary Algorithms in Multiobjective Optimization , 1995, Evolutionary Computation.
[99] C. Esmon,et al. The roles of protein C and thrombomodulin in the regulation of blood coagulation. , 1984, The Journal of biological chemistry.
[100] J. Varner,et al. A Test of Highly Optimized Tolerance Reveals Fragile Cell-Cycle Mechanisms Are Molecular Targets in Clinical Cancer Trials , 2008, PloS one.
[101] M. A. Payne,et al. Effect of soluble tissue factor on the kinetic mechanism of factor VIIa: enhancement of p-guanidinobenzoate substrate hydrolysis. , 1996, Biochemistry.
[102] D. Sinha,et al. Functional characterization of platelet-bound factor XIa: retention of factor XIa activity on the platelet surface. , 1986, Blood.
[103] H. Kitano,et al. Computational systems biology , 2002, Nature.
[104] Dougald M Monroe,et al. A cell-based model of thrombin generation. , 2006, Seminars in thrombosis and hemostasis.
[105] James F. Antaki,et al. Computational Simulation of Platelet Deposition and Activation: I. Model Development and Properties , 1999, Annals of Biomedical Engineering.
[106] Kwang-Hyun Cho,et al. Dynamics of biological systems: role of systems biology in medical research , 2006, Expert review of molecular diagnostics.
[107] H. Tien,et al. The use of recombinant factor VIIa in trauma patients. , 2009, The Journal of the American Academy of Orthopaedic Surgeons.
[108] K. Mann,et al. Biochemistry and Physiology of Blood Coagulation , 1999, Thrombosis and Haemostasis.
[109] P. A. von dem Borne,et al. Feedback activation of factor XI by thrombin in plasma results in additional formation of thrombin that protects fibrin clots from fibrinolysis. , 1995, Blood.
[110] S. Béguin,et al. The Calibrated Automated Thrombogram (CAT): a universal routine test for hyper- and hypocoagulability , 2002, Pathophysiology of Haemostasis and Thrombosis.
[111] Pål Aukrust,et al. Early anti-thrombotic and anti-inflammatory actions of statins and fibrates – time for adjuvant therapy in acute coronary syndromes? , 2005, Thrombosis and Haemostasis.
[112] G. Parmigiani,et al. Core Signaling Pathways in Human Pancreatic Cancers Revealed by Global Genomic Analyses , 2008, Science.
[113] Alisa S Wolberg,et al. A Variant of Recombinant Factor VIIa With Enhanced Procoagulant and Antifibrinolytic Activities in an In Vitro Model of Hemophilia , 2007, Arteriosclerosis, thrombosis, and vascular biology.